Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus

International Journal of Dermatology

Volumn 39, Issue 5, 2000, Pages 383-388

  Walchner, Monika ^a   Meurer, Michael ^a   Plewig, Gerd ^a   Messer, Gerald ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Dept of Dermatology and Allergology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; ESTROGEN; METHYLPREDNISOLONE; ORAL CONTRACEPTIVE AGENT; THALIDOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; ERYTHEMA; FATIGUE; FEMALE; HAIR GROWTH; HUMAN; LUPUS ERYTHEMATOSUS; LYMPHOCYTE COUNT; MALE; POLYNEUROPATHY; REMISSION; SKIN INJURY; TREMOR;

ADULT; ANTIBODIES, ANTINUCLEAR; C-REACTIVE PROTEIN; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; THALIDOMIDE;

EID: 0034072592     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2000.00866.x     Document Type: Article

References (27)

1. Hales BF. Thalidomide on the comeback trail. Nat Med 1999; 5: 489-490.
2. Calderon P, Anzilotti M, Phelps R. Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 1997; 36: 881-887.
3. Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996; 35: 969-979.
4. Ochonisky S, Revuz J. Thalidomide use in dermatology. Eur J Dermatol 1994; 4: 9-15.
5. Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 1998; 26: 217-221.
6. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589.
7. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996; 2: 86-92.
8. McHugh SM, Rowland TL. Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-α) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 1997; 110: 151-154.
9. Walchner M, Messer G, Wierenga EA, et al. Reconstitution of transcription factor binding to the conserved lymphokine element-o and downregulation of NF-kB activity after thalidomide treatment of systemic lupus erythematosus. (Abstract.) Arch Dermatol Res 1995; 287: 347.
10. D'Amato RJ, Loughnan MS, Flynn E, Folkmann J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
11. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl J Med 1991; 26: 1055-1058.
12. Oliver SJ, Cheng TP, Banquerigo ML, Brahn F. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol 1998; 25: 964-969.
13. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993; 11: 487-493.
14. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997; 36: 353-359.
15. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108: 461-466.
16. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Arch Dermatol 1983; 119: 812-815.
17. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Thalidomide-induced neuropathy in rheumatoid arthritis. Arthritis Rheum 1988; 31: 145-146.
18. Haslett P, Tramontana J, Burroughs M, et al. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 1223-1227.
19. Sontheimer RD. The lexicon of cutaneous lupus erythematosus-a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 84-95.
20. Walchner M, Messer G, Kind P. Phototesting and photoprotection in LE. Lupus 1997; 6: 167-174.
21. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol 1994; 12: 141-179.
22. Gruss HJ, Dower SK. Tumour necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378-3404.
23. Clement MV, Stamenkovic I. Fas and tumour necrosis factor receptor-mediated cell death: similarities and distinctions. J Exp Med 1994; 180: 557-567.
24. Holm AL, Bowers KE, McMeekin TO, Gaspari AA. Chronic cutaneous lupus erythematosus treated with thalidomide. Arch Dermatol 1993; 129: 1548-1550.
25. + T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 1996; 135: 211-217.
26. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-167.
27. + T cells in vitro. J Immunol 1996; 156: 2406-2412.